Brief: Burning Rock Announces In-Licensing Of Myriad Mychoice® Tumor Testing In China
16/11/2020 01:04
Nov 15 (Reuters) - Burning Rock Biotech Ltd BNR.O :
* BURNING ROCK ANNOUNCES IN-LICENSING OF MYRIAD MYCHOICE®
TUMOR
TESTING IN CHINA
Source text for Eikon: ID:nGNX8n1YVD
Further company coverage: BNR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Burning Rock Biotech
See all newsBurning Rock Biotech's Q2 revenue falls, net loss widens on central laboratory weakness
China's Burning Rock Biotech Q1 revenue falls on lower test volumes
China's Burning Rock Biotech Q4 net loss narrows as costs fall
Cancer diagnostics firm Burning Rock Biotech's Q3 revenue rises on pharma R&D growth
Brief: Burning Rock's Oncoguide™ Oncoscreen™ Plus CDX System Now Approved In Japan As A Companion Diagnostic For Capivasertib In Breast Cancer